Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options
An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.
A phase III study exploring the MET inhibitor onartuzumab as a treatment for patients with NSCLC is being stopped, following an interim analysis that suggested a lack of clinically meaningful efficacy.
For the first time, physicians have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.
In an interview with OncLive, Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center, University of South Florida, Tampa, explored the utilization of molecular and immune-targeted therapies as treatments for patients with advanced melanoma.
The second-line administration of ramucirumab in combination with docetaxel has shown a statistically significant improvement in overall survival and progression-free survival compared with placebo plus docetaxel in patients with non-small cell lung cancer
Giants of Cancer Care is now accepting nominations for the 2014 awards program.
The FDA has expanded the approval of ibrutinib to include the treatment of patients with chronic lymphocytic leukemia who have received at least one previous therapy.